Login to Your Account



In The Clinic NEWS

"This is an exciting opportunity for us," Rich Daly, chairman and CEO of Neuralstem Inc., said about top-line phase II data of NSI-189 to treat major depressive disorder (MDD).

HONG KONG – The Chinese drug registration authority has approved the phase III trial of a cancer drug in the first open meeting it ever held, clearing the way for late-stage testing of an oncolytic immunotherapy drug developed by Korean biopharma company Sillajen Inc. and its Chinese partner, Lee's Pharmaceutical Holdings Ltd.

As investors waited Wednesday afternoon for Sarepta Therapeutics Inc.'s second-quarter earnings, news of a MAP with Clinigen Group plc's Idis division for Exondys 51 in DMD had Wall Street speculating that the deal would add to fiscal-year 2017 guidance of more than $95 million.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: